Rational design of a triple-type HPV53/56/66 vaccine with one preferable base particle incorporating two identified immunodominant sites.
Qian C, Chen J, Yang Y, Lu Y, Ren T, Jiang Y, Huang Y, Chi X, Zhang S, Zhang C, Li K, Shen J, Zhang S, Wang D, Zhou L, Li T, Zheng Q, Yu H, Gu Y, Xia N, Li S.
Qian C, et al. Among authors: gu y.
J Nanobiotechnology. 2025 Jan 20;23(1):28. doi: 10.1186/s12951-024-03080-5.
J Nanobiotechnology. 2025.
PMID: 39828682